Loading clinical trials...
Loading clinical trials...
Phase 1/2 Study to Evaluate the Safety and Preliminary Activity of Nivolumab in Combination With Vorolanib in Patients With Refractory Thoracic Tumors
Conditions
Interventions
Vorolanib
Nivolumab
Locations
7
United States
Stanford Cancer Institute
Palo Alto, California, United States
Winship Cancer Institute, Emory University
Atlanta, Georgia, United States
University of Chicago Medical Center
Chicago, Illinois, United States
Providence Cancer Institute Franz Clinic
Portland, Oregon, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Baptist Clinical Research Institute
Memphis, Tennessee, United States
Start Date
July 10, 2018
Primary Completion Date
February 21, 2024
Completion Date
April 27, 2024
Last Updated
October 8, 2024
NCT06043817
NCT07144280
NCT06758401
NCT07431827
NCT06427941
NCT06476808
Lead Sponsor
Vanderbilt-Ingram Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions